EMA Authorised: Enrylaze (crisantaspase) — Jazz Pharmaceuticals Ireland Limited

View source ↗

Summary

Enrylaze (crisantaspase) has been authorised by the EMA for precursor cell lymphoblastic leukemia-lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Enrylaze (crisantaspase)

Snippet

Status: Authorised. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma. MAH: Jazz Pharmaceuticals Ireland Limited. Decision date: 16/02/2026